Three new aromatase inhibitors have recently completed phase III evaluation as treatment of metastatic breast cancer in postmenopausal women whose disease has progressed despite tamoxifen therapy: anastrozole (ARIMIDEX, Zeneca), letrozole (FEMARA, Novartis) and vorozole (RIVIZOR, Janssen). All belong to the third generation of non-steroidal aromatase inhibitors, and each is superior to previous generations in terms of potency and selectivity.
Introduction
There has never been consensus regarding the optimal second line hormonal therapy for breast cancer. For many years megestrol acetate and aminogluthethimide have competed in the market place, as no study has ever convincingly displayed a clear advantage of one over the other in terms of efficacy. Until very recently, it could be said that the hormonal pathway retained meaningful, though limited, therapeutic potential following tamoxifen, but that the various hormonal therapies were effectively equivalent in terms of efficacy in this setting. Few believed that increased efficacy was still possible in second-line hormonal treatment, as this therapeutic uniformity of different agents was assumed to reflect achievement of something close to the full antitumour potential of the hormonal pathway. The objective in the development of new agents has therefore been primarily that of reduced toxicity.
However, the past two years have seen the emergence of three new agents for the hormonal treatment of metastatic breast cancer in postmenopausal women following tamoxifen: anastrozole (ARIMIDEX*, Zeneca), letrozole (FEMARA*, Novartis) and vorozole (RIVIZOR®, Janssen). All are third-generation nonsteroidal aromatase inhibitors. Each has been presented as a therapeutic breakthrough, challenging our assumptions of the therapeutic limitations of second-line hormonal therapy. But are they better than our standard therapies, and if so, is any one of them superior to the others?
The first question has now been addressed in, and answered by, a series of randomised phase III trials, whose design and results are reviewed here. The answer to the second can unfortunately only yet be inferred with extreme caution, as no direct comparison of the three agents yet exists.
The anastrozole and letrozole trials have now been published in peer reviewed journals, however the anastrozole publications present a single analysis of two separately conducted trials, with few details of the results of the individual trials. The vorozole trials have been presented only as abstracts. For the purpose of this review, we have also included data from pharmaceutical industry sources when they were not available from the publications (indicated in italics in the tables). The data that we present are not complete, as none of the trials or reports were designed for the purpose of this review, but they reflect the available information at a time when anastrozole and letrozole have completed their registration formalities both in North America and in Europe. Registration procedures will not proceed for vorozole, following criticism by the American Food and Drug Administration of the schedule of response evaluations in the vorozole trials (organs that were not involved at baseline were not required to be systematically followed, potentially introducing bias into progression dates), and the drug's development has subsequently been abandoned by Janssen. The data from the vorozole trials have been retained in this review, however, as they nevertheless contribute to our understanding of this generation of aromatase inhibitors. Table 1 summarises the results of the randomised trials of the three aromatase inhibitors, using only the dose of each new agent that has been selected for registration purposes. This Table is a summary only of the statistical significance of results in the trials, and must therefore be viewed with the problems of interpreting P-values in mind. Such an overview, however, has uses despite this limitation. Firstly, it can be seen that each of the new agents displayed significant advantages over conventional therapy in both efficacy and/or toxicity endpoints. Secondly, none of the agents was significantly inferior to conventional therapy in any efficacy or toxicity endpoint. Although it would appear that letrozole has performed the most impressively of the three, it would be unwise to attempt to compare the three agents from the results presented in this table, as they are clearly biased by differences in both trial design, and the patient populations which were studied.
The trials

The patient populations
To demonstrate this, the design of the trials (Table 2) , the eligibility criterias (Table 3 ) and the trial populations (Table 4) can be compared.
There are three important features of the trials evident from Table 2 . Firstly, there was no clear consensus in the selection of primary end point. Time to progression was thought to hold more weight than response rate by the vorozole investigators, but both of the trials of this drug were eventually reported in terms of response rate, at the request of the FDA. Fortunately, both trials of this drug were well powered, and this did not influence the result of the studies. The endpoint of 'clinical benefit' is reported in most of the trials, and uses a common definition (CR + PR + NC > 6 months). It is not reproduced here as it does not belong to any published response evaluation criteria, and because the term is ambiguous in that it does not specify whether patients who achieve a response but progress before six months of therapy should be included. The endpoint is an attempt to combine response rate (RR) with progression free survival at six months (PFS six months), but reflects neither accurately. Its addition to the list of trial endpoints merely increases the probability of finding a statistically significant result in the trial, while adding little to the information provided by conventional endpoints. If an additional endpoint is truly required, PFS 6mo more accurately reflects the concept of treatment efficacy that 'clinical benefit' attempts to express. This endpoint, however, has not been reported in these trials.
The second feature is that the letrozole investigators were alone in double-blinding their trial versus megestrol acetate. Although one can not know the degree to which this may alter the results of a trial such as this, it implies an objectivity that adds significant weight to the strength of the data that has strongly supported the new drug. Finally, the method of follow up was not uniform across trials. Imaging of baseline lesions was repeated every two months, every three months, or every two months with additional imaging one month following the first documentation of a clinical response, depending on the trial. The impact of this is unclear, but it may have influenced the endpoints of time to progression (TTP) and time to treatment failure (TTF). In the vorozole trials, the failure to systematically follow organs that were not involved at baseline led to criticism of the reliability of the dates of progression in those trials. Table 3 demonstrates the variability that exists in defining a hormone-sensitive patient population. Each trial defined its target population differently, and the vorozole trials were stricter in their definitions of potential hormone responsiveness than the others.
Additionally, all trials included patients with evaluable disease, and the vorozole versus megestrol acetate trial was alone in including patients with non-evaluable disease as well. As nonmeasurable disease should not have been assessed as being in PR (only CR, NC and PD are possible outcomes), this should have reduced the percentage of patients with reportable responses in all trials, probably to different extents, and the final impact of this factor on reported response rates is uncertain.
A final point is that response in bone is open to interpretation even when lesions are lytic and measurable, and when formal response criteria are used. The possibility that response rates were additionally influenced by different interpretations of the definition of response in bone should not be ignored. Table 4 attempts to demonstrate the impact of variations in eligibility criteria on the eventual trial populations. Unfortunately many of the patient demographics have not been presented, or have been presented using different styles of presentation so that comparisons are not possible. Such comparison would be useful also to demonstrate any impact of competing trials on the patients who were selected for these trials. A surrogate method of comparison of trial populations is shown in Table 5 , which compares the results in the control arms of the trials. In the trials using megestrol acetate, there is no clear pattern to suggest that any of the trials had selected a population that was particularly more hormone-sensitive than either of the others. For example, the control arm of the letrozole study, which displayed the highest response rate of the three, also displayed the shortest overall survival. Comparison of the results of the control arms in the aminoglutethimide trials is suggestive, however, that the vorozole trial may have studied a more hormonally-sensitive population than the letrozole trial. This may be a reflection of the differences in inclusion criteria of the trials.
Results
Tables 6-9 summarise the available results of the trials versus megestrol acetate, and Tables 10 and 11 summarise the available results of the trials versus aminogluthimide. The absence of full publications of the vorozole trials in peer-reviewed journals obviously severely limits the interpretations that can be safely made, however the following conclusions can be drawn:
No data exists to allow comparison of anastrozole and aminoglutethimide. 2. The optimal dose of anastrozole is probably 1 mg od. There is no added benefit from the 10 mg od dose. 3. Anastrozole has not convincingly displayed an advantage over megestrol acetate in terms of efficacy. 4. Anastrozole is well tolerated, with an advantage over megestrol acetate in terms of weight gain.
Letrozole 5. The optimal dose of letrozole is probably 2.5 mg od. This dose is superior to 0.5 mg od. 6. Letrozole is superior to both megestrol acetate and aminoglutethimide in terms of both efficacy and tolerability. Vorozole 7. Vorozole, at a dose of 2.5 mg od, is superior to aminoglutethimide in terms of toxicity and possibly in efficacy. 8. Vorozole has not demonstrated an advantage over megestrol acetate in terms of efficacy, but it is better tolerated, specifically in terms of weight gain. This of course leads to the question of which of the three is the most effective non-steroidal aromatase inhibitor in breast cancer.
In vivo data describe a continuum of inhibition of aromatase, with aminoglutethimide (90%), vorozole (93%), anastrozole (97%), and finally letrozole (98.5%) displaying increasing potency and specificity (Geisler et al. 1996) . This, however, can not be interpreted to mean that letrozole is the most effective agent clinically, as we do not yet know if there is a threshold of aromatase inhibition above which no additional therapeutic advantage is realised, or whether there is a continuum of clinical efficacy that mirrors the pharmacology of the drugs.
The trials versus aminoglutethimide
The trials comparing aminoglutethimide to each of vorozole and letrozole have shown that each of these new agents is superior to the historical control. While vorozole was significantly better in terms of 'clinical benefit', time to treatment failure and quality of life, letrozole was superior in terms of duration of 'clinical benefit', time to progression, time to treatment failure and overall survival. From these data, it can be concluded that if a maximal level of useful aromatase inhibition does exist, it must be at a level higher than that achieved by aminoglutethimide. But we still can not predict whether letrozole would display an advantage over vorozole if the two were compared, as we do not know whether the clinical effect of aromatase inhibition plateaus at high levels.
The toxicity profile of both new agents was better than that of aminoglutethimide. Specifically, the incidence of rash was significantly reduced in the experimental arm of both trials, the incidence of somnolence was significantly reduced in the vorozole arm of the vorozole trial, and significantly more patients receiving aminoglutethimide ceased treatment due to adverse events than those on either of the experimental arms.
Attempts at indirect comparison of the two new agents are impossible as the patient populations were clearly not the same, and unfortunately no trial exists of anastrozole versus aminoglutethimide, so we have no information about how this agent compares clinically to any other member of its family.
Despite these difficulties, it is clear that aminoglutethimide is now obsolete, as it has been surpassed by at least two agents with the same mechanism of action in terms of efficacy, toxicity and ease of administration.
The trials versus megestrol acetate
These trials address the issue of whether effective aromatase inhibition is superior to progestins in the second-line hormonal therapy of breast cancer.
Two trials were performed comparing anastrozole to megestrol acetate: one in North America and the other in Europe, Australia and South Africa. A survival advantage was demonstrated for anastrozole lmg od over megestrol acetate in the 'European' trial (P = 0.048) that persisted when the two trials were combined (P = 0.025). The credibility of this result, however, is weakened by several observations that highlight the difficulties of the interpretation of an isolated statistically significant result:
1. No survival advantage was seen in the North American trial. Overall survival was longer in the anastrozole 1 mg od arm than the megace arm but the p-value could not even indicate a trend (P = 0.34).
The individual trials were not designed with the power to detect a survival advantage when analysed separately, which makes this observation difficult to interpret, however a stronger result in the North American trial would have given needed support to the result of the combined trials. 2. No advantage is seen in any other efficacy endpoint of the combined trials. Unfortunately the data of the individual trials remain unreported beyond the number of participating centres and the survival figures. Although it remains possible that the unreported data in these individual trials are strongly supportive of anastrozole, the probability of this must be small. 3. No survival advantage was demonstrated for the higher dose (10 mg od) of anastrozole, although there was a trend towards longer survival for the 10 mg od dose versus megestrol acetate in the combined trials (P = 0.09).
Of the three arms in the combined anastrozole trials, the 1 mg dose performed the strongest in terms of absolute survival, but this was not statistically different to the 10 mg od dose. The most likely explanation of this is that there is no added benefit to be gained from the higher dose. However the combined trials were well powered to detect a survival difference between arms, and it is therefore likely that there has been a statistical aberration in these trials that has either failed to detect a true survival advantage of the 10 mg od dose over megestrol acetate, or that has falsely detected an advantage for the 1 mg od dose. Either way, any interpretation of the survival data from these trials must be made with extreme caution. Letrozole was the only one of the three agents to display a clear advantage over megestrol acetate in terms of efficacy. Letrozole was also superior in terms of response rate, response duration, duration of 'clinical benefit" and time to treatment failure.
Like anastrozole, vorozole struggled to display a clear advantage over megestrol acetate in terms of efficacy. Although most trial endpoints favoured vorozole, no statistically significant result was documented. A trend was seen in favour of vorozole in response duration (P = 0.07).
The quality of life reports from these four trials illustrate the difficulty in assessing this endpoint. The QOL assessments in the two anastrozole trials were not of the same design and have therefore never been reported. In the vorozole versus megestrol acetate trial, there was a significant difference in one aspect of QOL between the two arms at baseline, and results were therefore difficult to interpret. Despite significant differences in other efficacy endpoints in the letrozole trial, no difference in QOL was demonstrated. Patients treated with letrozole experienced less deterioration in performance status than those treated with megestrol acetate.
As regards toxicity, all three new agents display a clear advantage over megestrol acetate in terms of weight gain. Anastrozole at the dose of lOmg od produced significantly more gastrointestinal disturbance (nausea and vomiting) than megestrol acetate. There was no statistically significant difference in these toxicities between megestrol acetate and anastrozole at the lmg od dose. It is likely, however, that this class of agents does produce more nausea than megestrol acetate. All trials displayed more nausea and vomiting in patients treated with the new agents, though this was not significant in any but the abandoned anastrozole dose.
Letrozole-treated patients experienced significantly less drug-related serious adverse events than those treated with megestrol acetate.
As explained earlier, indirect comparison of the three agents is fraught with difficulties, due to the variation in trial design and reported patient population in these trials, but it can be said that letrozole is the only one of the three to have demonstrated an advantage over megestrol acetate in terms of efficacy.
Letrozole is clearly superior to megestrol acetate, and the other two agents are definite improvements, at least in terms of toxicity. Megestrol acetate is not yet obsolete, as its mechanism of action is different to the aromatase inhibitors, but it can now be said that it is suboptimal in second-line therapy.
Conclusions
Each of these three new aromatase inhibitors provides adequate second-line hormonal therapy for breast cancer, with response rates of 10%-24%, and overall survival of approximately 24 months. They all display an advantage over standard therapy in terms of toxicity, most notably in terms of weight gain when compared to megestrol acetate, and rash and lethargy when compared to aminoglutethimide.
Letrozole appears to have performed particularly well in terms of efficacy versus the two current standard therapies, however the other two agents have also performed solidly, with vorozole also demonstrating clear superiority over aminoglutethimide. It is possible that these differing efficacy results are a reflection of the differing degrees of aromatase inhibition provided by the three drugs but it is just as likely that they are simply the result of variations in trial design and patient populations. Without direct comparison, the best thirdgeneration aromatase inhibitor at a clinical level remains undefined.
The third generation of aromatase inhibitors provides single-agent, once-daily, oral palliation of hormoneresponsive, postmenopausal metastatic breast cancer, that is overall better tolerated and more effective than each of our current standard second-line therapies. The next phase of investigation must address the optimal sequencing of these third-generation aromatase inhibitors with the steroidal aromatase inhibitors and the pure anti-oestrogens, and the role of these agents in schedules of alternating hormonal agents, particularly aiming to prolong the hormone-sensitive phase of the disease.
